“Abilify” (Otsuka Pharmaceutical and Bristol-Myers Squibb) was found guilty of providing financial incentives to pediatric physicians in order to promote the prescription of the drug to minors.
At the time, Abilify was not approved by the Food and Drug Administration (FDA) for pediatric use.
2007: “Bristol-Myers Squibb to Pay More Than $515 Million to Resolve Allegations of Illegal Drug Marketing and Pricing”
(Source: US Department of Justice)
2008: “Otsuka to Pay More than $4 Million to Resolve off-label Marketing Allegations Involving Abilify”
(Source: US Department of Justice)
FDA Pediatric Approval Timeline
The Food and Drug Administration (FDA) has approved Abilify as “safe and effective” for the treatment of the following disorders:
October 2007: Schizophrenia (ages 13-17)
February 2008: Bipolar I Disorder (ages 10-17)
November 2009: Irritability associated with Autism Spectrum Disorder (ages 6-17)
December 2014: Tourette’s Syndrome (ages 6-17)
Abilify Survey 